Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 63 | ECE2019 | Next issue

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

Card image cap
18-21 May 2019, Lyon, France

Guided Posters

Acromegaly and GH

Previous section
Metabolic Syndrome and Hypoglycaemia
Table of contents
Next section
Reproductive Axis

ea0063gp48 | Acromegaly and GH

Prolonged diagnostic delay in acromegaly is associated with long-term morbidity and excess mortality: data from a nationwide study

ea0063gp49 | Acromegaly and GH

Pharmacokinetics of somapacitan in individuals with renal impairment: an open-label, parallel group, phase 1 study

ea0063gp50 | Acromegaly and GH

Sleep disorders and cognitive dysfunction in acromegaly

ea0063gp51 | Acromegaly and GH

Prognostic value of short-acting pasireotide test for response prediction to pasireotide LAR in patients with acromegaly resistant to first-generation analogs. Can a short-acting pasireotide test predict the response of long-acting pasireotide treatment in patients with acromegaly resistant to first generation somatostatin analogs?

ea0063gp52 | Acromegaly and GH

Final height in childhood onset hypopituitarism

ea0063gp53 | Acromegaly and GH

Efficacy and safety of once-weekly somapacitan in adult growth hormone deficiency (AGHD) confirmed in a 53-week REAL-1 trial extension

ea0063gp54 | Acromegaly and GH

Pharmacokinetics in patients with prolactinomas

ea0063gp55 | Acromegaly and GH

Acromegaly do not increase the risk of vertebral fractures: a retrospective and prospective study on 50 patients

ea0063gp56 | Acromegaly and GH

Sclerostin and fracture risk assessment in acromegaly

ea0063gp57 | Acromegaly and GH

Biochemical control was sustained with long-acting pasireotide in patients with uncontrolled acromegaly over continued treatment with first-generation somatostatin analogues (SSAs): Results from the extension of phase 3b, open-label study

ea0063gp58 | Acromegaly and GH

ACROSTUDY – safety and efficacy in a cohort of 110 Naïve patients with acromegaly treated with pegvisomant

ea0063gp59 | Acromegaly and GH

Effects of pegvisomant and pasireotide LAR on incidence of vertebral fractures in patients with acromegaly resistant to treatment with first-line somatostatin analogs

ea0063gp60 | Acromegaly and GH

Metabolic outcome in adolescents with growth hormone deficiency during transition phase

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more